E
Ephraim P. Hochberg
Researcher at Harvard University
Publications - 166
Citations - 7484
Ephraim P. Hochberg is an academic researcher from Harvard University. The author has contributed to research in topics: Rituximab & Lymphoma. The author has an hindex of 46, co-authored 157 publications receiving 6442 citations. Previous affiliations of Ephraim P. Hochberg include Hebrew University of Jerusalem & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
David B. Miklos,David B. Miklos,Haesook T. Kim,Haesook T. Kim,Katherine Miller,Katherine Miller,Luxuan Guo,Luxuan Guo,Emmanuel Zorn,Emmanuel Zorn,Stephanie J. Lee,Stephanie J. Lee,Ephraim P. Hochberg,Ephraim P. Hochberg,Catherine J. Wu,Catherine J. Wu,Edwin P. Alyea,Edwin P. Alyea,Corey Cutler,Corey Cutler,Vincent T. Ho,Vincent T. Ho,Robert J. Soiffer,Robert J. Soiffer,Joseph H. Antin,Joseph H. Antin,Jerome Ritz,Jerome Ritz +27 more
TL;DR: The presence of H-Y antibodies correlated with chronic graft-versus-host disease (GVHD) and antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antIGens) was also associated with maintenance of disease remission (P < .0001).
Journal ArticleDOI
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Matija Snuderl,Olga K. Kolman,Yi Bin Chen,Jessie J. Hsu,Adam M. Ackerman,Paola Dal Cin,Judith A. Ferry,Nancy L. Harris,Robert P. Hasserjian,Lawrence R. Zukerberg,Jeremy S. Abramson,Ephraim P. Hochberg,Hang Lee,Alfred Ian Lee,Christiana E. Toomey,Aliyah R. Sohani +15 more
TL;DR: DHL is a high-grade B-cell neoplasm with a poor prognosis, resistance to multiagent chemotherapy, and clinical and pathologic features distinct from other high- grade B- cell neoplasms.
Journal ArticleDOI
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe O. Odejide,Oliver Weigert,Oliver Weigert,Andrew A. Lane,Dan Toscano,Matthew A. Lunning,Nadja Kopp,Sunhee Kim,Diederik van Bodegom,Sudha Bolla,Jonathan H. Schatz,Jonathan H. Schatz,Julie Teruya-Feldstein,Ephraim P. Hochberg,Abner Louissaint,David M. Dorfman,Kristen E. Stevenson,Scott J. Rodig,Pier Paolo Piccaluga,Eric D. Jacobsen,Stefano Pileri,Nancy L. Harris,Simone Ferrero,Giorgio Inghirami,Steven M. Horwitz,David M. Weinstock +25 more
TL;DR: The mutational landscape of AITL is characterized by high frequencies of overlapping mutations in epigenetic modifiers and targetable mutations in a subset of cases.
Journal ArticleDOI
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project.
Jan Delabie,Harald Holte,Julie M. Vose,Fred Ullrich,Elaine S. Jaffe,Kerry J. Savage,Joseph M. Connors,Lisa M. Rimsza,Nancy L. Harris,Konrad Müller-Hermelink,Thomas Rüdiger,Bertrand Coiffier,Randy D. Gascoyne,Françoise Berger,Kensei Tobinai,Wing Yan Au,Raymond Liang,Emili Montserrat,Ephraim P. Hochberg,Stefano Pileri,Massimo Federico,Bharat N. Nathwani,James O. Armitage,Dennis D. Weisenburger +23 more
TL;DR: The study confirms the poor prognosis of patients with EATL and the need for improved treatment options and the International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostics Index for Peripheral T-Cell Lymphoma (PIT).
Journal ArticleDOI
Antibody response to H-Y minor histocompatibility antigens correlates with chronic graft versus host disease and disease remission
David B. Miklos,Haesook T. Kim,Katherine Miller,Luxuan Guo,Emmanuel Zorn,Ephraim P. Hochberg,Saem Lee,Robert J. Soiffer,Joseph H. Antin,Jerome Ritz +9 more
TL;DR: The presence of H-Y antibodies correlated with chronic graft-versus-host disease (GVHD) by univariate and multivariable logistic regression analysis and was also associated with maintenance of disease remission (P < .0001).